Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.

The pharmacogenomics journal - 1 Dec 2018

Hongkaew Yaowaluck, Medhasi Sadeep, Pasomsub Ekawat, Ngamsamut Nattawat, Puangpetch Apichaya, Vanwong Natchaya, Chamnanphon Monpat, Limsila Penkhae, Suthisisang Chuthamanee, Wilffert Bob, Sukasem Chonlaphat

Abstract excerpt

The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients. Eighty-four ASD patients who were receiving risperidone for at least 1 month were recruited and then assigned to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Autism Spectrum Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Prolactin

Share to Risperidone

Share to Thailand

Source

Identifiers

PMID: 29955115
DOI: 10.1038/s41397-018-0031-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.PMID 29955115Read ↗

Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implicationsSemantic proximity Read ↗

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.Semantic proximity Read ↗

Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.Semantic proximity Read ↗

Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder.Semantic proximity Read ↗

The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.Semantic proximity Read ↗

Pharmacogenetics of Clinical Response to RisperioneSemantic proximity Read ↗

Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in healthy volunteers. Association with pharmacogeneticsSemantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis.Semantic proximity Read ↗

The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.